NEW YORK — Luminex, a DiaSorin company, said on Tuesday that it has received CE marking for its xMap NxTag Gastrointestinal Pathogen Panel (GPP), a molecular multiplex panel for the detection of 16 different pathogens.
The stool-based test covers pathogens associated with gastrointestinal infections including eight types of bacteria such as C. difficile, Salmonella, and Campylobacter; five types of viruses including norovirus and rotavirus; and three parasites, including Giardia lamblia. It can run up to 96 samples at a time on Luminex's Magpix instrument and provides same-day results.
"With this CE marking, clinical laboratories across Europe will be able to streamline testing for patients exhibiting gastrointestinal symptoms using the NxTag GPP test," Luminex President Nachum Shamir said in a statement. "In particular, labs that are already using the NxTag system for respiratory infection testing should find it easy to expand their test menus with this cost-effective NxTag GPP test."
About one year ago, Austin, Texas-based Luminex was acquired by Italy's DiaSorin for $1.8 billion in cash.